Friday, September 08, 2023
Biocytogen Pharmaceuticals and Myricx Bio have entered into an antibody evaluation, option, and licence agreement to collaborate on the development of antibody drug conjugates (ADCs).
This partnership leverages the strengths of both companies to create ADC drugs that have the potential to be first-in-class and best-in-class in the field of oncology.
This collaboration brings together the groundbreaking NMTi-based selective cytotoxic payloads with Biocytogen's expertise in antibody development for drug development purposes. This combination is expected to yield ADCs that can address significant clinical needs in the treatment of cancer.
NMT inhibitors represent a novel class of ADC payloads that hold promise as targeted therapies for cancer. These inhibitors work through a unique mechanism of action, which is distinct from traditional approaches to cancer treatment. ADC-NMTi has enormous potential for selectively killing cancer cells. This innovative approach offers a new way to target cancer with precision and effectiveness.
The collaboration between Biocytogen Pharmaceuticals and Myricx Bio aims to harness the strengths of both companies to develop groundbreaking ADCs that can provide significant advancements in cancer therapy. The use of NMT inhibitors as ADC payloads represents an exciting avenue for the development of selective and potent cancer treatments.
